Head and neck - oncology - SA Health Approved Cancer Chemotherapy Protocol Register

Definitive chemoradiation

Definitive Chemoradiation
Protocol Administration at chemotherapy unit level Review Date
Head and neck squamous cell carcinoma locally advanced cARBOplatin (weekly) chemoradiation (Part 2 of TPF) Medium August 2024
Head and neck squamous cell carcinoma locally advanced definitive cARBOplatin and fluorouracil chemoradiation Medium August 2024
Head and neck squamous cell carcinoma locally advanced definitive cetuximab chemoradiation Medium August 2024
Head and neck squamous cell carcinoma locally advanced definitive cISplatin (three weekly) chemoradiation Medium August 2021
Head and neck squamous cell carcinoma locally advanced definitive cISplatin (weekly) chemoradiation Medium August 2021

Induction chemotherapy

Induction Chemotherapy
Protocol Administration at chemotherapy unit level Review Date
Head and neck squamous cell carcinoma locally advanced induction TPF (DOCEtaxel cISplatin fluorouracil) (part 1) Medium August 2024

Nasopharyngeal

Nasopharyngeal
Protocol Administration at chemotherapy unit level Review Date
Nasopharyngeal locally advanced adjuvant cARBOplatin and fluorouracil (following chemoradiation) Medium August 2024
Nasopharyngeal locally advanced adjuvant cISplatin and fluorouracil (following chemoradiation) Medium August 2024
Nasopharyngeal locally advanced cARBOplatin (weekly) chemoradiation Medium August 2024
Nasopharyngeal locally advanced cISplatin (three weekly) chemoradiation Medium August 2024
Nasopharyngeal locally advanced cISplatin (weekly) chemoradiation Medium August 2024
Nasopharyngeal recurrent or metastatic cISplatin and gemcitabine Medium Day 1
Low day 8
August 2024
Nasopharyngeal recurrent or metastatic gemcitabine Low August 2024

Post operative chemoradiation

Post operative chemoradiation
Protocol Administration at chemotherapy unit level Review Date
Head and neck squamous cell carcinoma locally advanced post operative cISplatin (three weekly) chemoradiation Medium August 2024
Head and neck squamous cell carcinoma locally advanced post operative cISplatin (weekly) chemoradiation Medium February 2022

Recurrent or metastatic

Recurrent or Metastatic
Protocol Administration at chemotherapy unit level Review Date
Head and neck squamous cell carcinoma recurrent or metastatic cARBOplatin and fluorouracil Medium2 August 2024
Head and neck squamous cell carcinoma recurrent or metastatic cARBOplatin and PACLitaxel Medium August 2022
Head and neck squamous cell carcinoma recurrent or metastatic cARBOplatin fluorouracil and cetuximab Medium - Day 1. Low - Day 8 and 15. Moves to full low risk after completion of cARBOplatin/fluorouracil treatment) August 2024
Head and neck squamous cell carcinoma recurrent or metastatic cISplatin (three weekly) and fluorouracil Medium2 August 2024
Head and neck squamous cell carcinoma recurrent or metastatic ciSplatin and capecitabine Medium August 2022
Head and neck squamous cell carcinoma recurrent or metastatic cISplatin fluorouracil and cetuximab Medium Day 1. Low Day 8 and 15. Moves to low risk after completion of cISplatin treatment) August 2024
Head and neck squamous cell carcinoma recurrent or metastatic methotrexate Low August 2024
Head and neck squamous cell carcinoma recurrent or metastatic PACLItaxel Medium August 2024
Advanced or Metastatic nivolumab (flat dosing) Low August 2021
Advanced or Metastatic nivolumab (weight based dosing) Low August 2021
Advanced, metastatic or recurrent pembrolizumab
Low February 2022

Salivary gland

Salivary Gland
Protocol Administration at chemotherapy unit level Review Date
Head and neck salivary gland advanced CAP (CYCLOPHOSPHamide DOXOrubicin cISplatin) Medium February 2024
Head and neck salivary gland advanced or metastatic ciSplatin and vinORELBine Medium August 2022

Thyroid

Thyroid
Protocol Administration at chemotherapy unit level Review Date
Thyroid locally advanced or metastatic lenvatinib Low August 2021

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.